Cargando…
Pirfenidone suppressed triple‐negative breast cancer metastasis by inhibiting the activity of the TGF‐β/SMAD pathway
Among breast cancer patients, metastases are the leading cause of death. Despite decades of effort, little progress has been made to improve the treatment of breast cancer metastases, especially triple‐negative breast cancer (TNBC). The extracellular matrix plays an important role in tumour growth a...
Autores principales: | Luo, Daiqin, Zeng, Xianlin, Zhang, Shuling, Li, Daohong, Cheng, Zhimei, Wang, Yun, Long, Jinhua, Hu, Zuquan, Long, Shiqi, Zhou, Jing, Zhang, Shuai, Zeng, Zhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889661/ https://www.ncbi.nlm.nih.gov/pubmed/36651490 http://dx.doi.org/10.1111/jcmm.17673 |
Ejemplares similares
-
Pirfenidone Alleviates Choroidal Neovascular Fibrosis through TGF-β/Smad Signaling Pathway
por: Gao, Chuang, et al.
Publicado: (2021) -
Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling
por: Jiang, Hong-Lin, et al.
Publicado: (2015) -
Inhibition of TGF-β2–Induced Trabecular Meshwork Fibrosis by Pirfenidone
por: Zhu, Xiaofeng, et al.
Publicado: (2023) -
Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren’s disease -derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2019) -
Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer
por: Lin, Xuan, et al.
Publicado: (2021)